iX Biopharma

SINGAPORE (Feb 8): iX Biopharma announced 2Q losses widened nearly fivefold to $3.24 million from $0.67 million a year ago.

SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs. The pro

SINGAPORE (Dec 15):  Catalist-listed iX Biopharma has launched a line of nutraceuticals – dietary supplements and fortified food products – that could help it turn a profit sooner than it could have done through the development of its pain management

SINGAPORE (Nov 8): Specialty pharmaceutical firm iX Biopharma saw its net losses quadruple to $3.2 million for the 1Q18 ended September, widening from a net loss of $0.8 million a year ago.

SINGAPORE (Oct 23): Specialty pharmaceutical firm iX Biopharma announced Monday that it has secured a European patent for its WaferiX drug delivery technology.

SINGAPORE (Aug 23): iX Biopharma, the specialty pharmaceutical company, reported net losses for FY17 ended June narrowed to $7.4 million from losses of $7.7 million a year ago.

SINGAPORE (May 15): Specialty pharmaceutical firm iX Biopharma on Monday incorporated a new wholly-owned subsidiary in Singapore, Entity Health, to promote and market the group’s supplements business.

SINGAPORE (Feb 8): iX Biopharma posted a net loss of $0.7 million in the quarter ended Dec 31, 2016, improving from a net loss of $2.4 million a year ago.

SINGAPORE (Nov 22): Here are some factors and stocks that could move the market this Tuesday morning:

SINGAPORE (Nov 21): Pharmaceutical company iX Biopharma announced that it has been granted a patent in South Africa for its WaferiX drug delivery technology. The patent will expire on Oct 26, 2030.